Raptinal

SKU: orb2900958

Description

Raptinal, a agent that directly activates caspase-3, initiates intrinsic pathway caspase-dependent apoptosis. Raptinal is able to rapidly induce cancer cell death by directly activating the effector caspase-3, bypassing the activation of initiator caspase-8 and caspase-9.

Key Properties

• CAS Number: 1176-09-6
• MW: 386.44
• Purity: >98% (HPLC)
• Formula: C₂₈H₁₈O₂
• SMILES: O=CC1(c2ccccc2-c2ccccc12)C1(C=O)c2ccccc2-c2ccccc12
• Target: Caspase
• Solubility: In Vitro: DMSO : 20 mg/mL (51.75 mM; Ultrasonic (<60°C)

Bioactivity

• In Vivo:
  Animal model: C57BL/6 and BALB/c female mice (6-8 weeks old) bearing the B16-F10 model or 4T1 models. Dosage: 20 mg/kg. Administration: Administered intraperitoneally; once daily for 3 consecutive days for B16-F10 and 4 consecutive days for 4T1 models. Result: Retard tumor volume and tumor mass by 60% relative to controls in the B16-F10 model. Similar efficacy was observed for the 4T1 murine breast cancer tumor model with 50% growth inhibition after treatment.
  Read more...
• In Vitro:
  Cell Viability Assay Cell line: Human Lymphoma U-937, SKW 6.4, or Jurkat cell lines Concentration: 0.7-3.4 μM Incubation time: 24 hours. Result: The IC50 values of Raptinal against U-937, SKW 6.4, or Jurkat cell lines were 1.1 ± 0.1, 0.7 ± 0.3, 2.7 ± 0.9 μM, respectively. Western blot analysis. Cell line: Human gastric cancer cell lines AGS, MKN28, MKN45. Concentration: 10 μM. Incubation time: 2 hours. Result: Induced apoptosis by activating caspase-3 within 30 min at a concentration of 10 μM. Treatment with 10 μM of Raptinal for 2 h induced the cleavage of pro-caspase-3 into it's active form in all three cell lines.
  Read more...

Storage & Handling

• Storage: Storage temperature: -20°C. Stability: ≥ 2 years
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Quick Database Links

Gene Symbol

Caspase